Clinical Trial Update: Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001) [Phase 2]

View source ↗

Summary

This clinical trial update notes that Balstilimab is being evaluated in a Phase 2 study (IMMONC0001) for relapsed/refractory lymphomas to assess safety and effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Balstilimab (balstilimab)

Snippet

Sponsor: Immune Oncology Research Institute | Conditions: Lymphoma | Phase 2 | Status: RECRUITING